1H-吲哚-6-羰酰氯 | 215941-02-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1H-吲哚-6-羰酰氯
• 中文别名: 6-羰基氯-1H-吲哚
• 英文名称: indol-6-ylcarbonyl chloride
• 英文别名: 1H-Indole-6-carbonyl chloride
• CAS: 215941-02-9
• 化学式: C₉H₆ClNO
• 分子量: 179.606
• InChiKey: ASPUVXAGGCKFAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1H-吲哚-6-羰酰氯 在 吡啶 、 硫酸 、 三乙酰氧基硼氢化钠 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Discovery of thiadiazole amides as potent, S1P3-sparing agonists of sphingosine-1-phosphate 1 (S1P1) receptor

  摘要：

  High-throughput screening of GSK compound collection led to the discovery of a novel series of thiadiazole amides as potent and S1P(3)-sparing sphingosine-1-phosphate 1 (S1P(1)) receptor agonists. Synthesis, structure and activity relationship, selectivity, and some developability properties are described. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.016
• 作为产物：
  描述：

  6-吲哚甲酸 在 1-氯-N,N,2-三甲基丙烯胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 1H-吲哚-6-羰酰氯
  参考文献：
  名称：

  Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328

  摘要：

  5-Fluoro-2-aryloxazolo[5,4-b]pyridines were synthesized and investigated as potential F-18 containing beta-amyloid PET ligands. In competition binding assays using human AD brain homogenates, compounds 14b, 16b, and 17b were identified as having favorable potency versus human beta-amyloid plaque and were radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. These studies led to the identification of 17b (MK-3328) as a candidate PET ligand for the clinical assessment of beta-amyloid plaque load.

  DOI：

  10.1021/ml200018n

文献信息

• [EN] NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES<br/>[FR] NOUVEAUX PYRAZOLES SUBSTITUÉS, 1,2,4-OXADIAZOLES, ET 1,3,4-OXADIAZOLES
  申请人：MERCK & CO INC

  公开号：WO2009146343A1

  公开（公告）日：2009-12-03

  The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted pyrazole derivatives, compositions, and therapeutic uses and processes for making such compounds.

  本发明涉及新型淀粉样蛋白结合化合物和测量这些化合物效果的方法，通过测量活体患者淀粉样斑块水平的变化。更具体地说，本发明涉及一种利用本发明化合物作为示踪剂在正电子发射断层扫描（PET）成像中研究活体大脑中淀粉样沉积以进行阿尔茨海默病诊断的方法。因此，本发明涉及将新型淀粉样蛋白结合化合物用作诊断的用途。该发明还涉及一种测量阿尔茨海默病治疗药物临床疗效的方法。具体而言，本发明涉及新型芳基或杂环芳基取代的吡唑衍生物、组成物和制备此类化合物的治疗用途和方法。
• Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors
  作者：Arun K. Ghosh、Gangli Gong、Valerie Grum-Tokars、Debbie C. Mulhearn、Susan C. Baker、Melissa Coughlin、Bellur S. Prabhakar、Katrina Sleeman、Michael E. Johnson、Andrew D. Mesecar

  DOI：10.1016/j.bmcl.2008.08.082

  日期：2008.10

  Design, synthesis and biological evaluation of a series of 5-chloropyridine ester-derived severe acute respiratory syndrome-coronavirus chymotrypsin-like protease inhibitors is described. Position of the carboxylate functionality is critical to potency. Inhibitor 10 with a 5-chloropyridinyl ester at position 4 of the indole ring is the most potent inhibitor with a SARS-CoV 3CLpro IC(50) value of 30

  描述了一系列5-氯吡啶酯衍生的严重急性呼吸综合征-冠状病毒糜蛋白酶样蛋白酶抑制剂的设计、合成和生物学评价。羧酸酯官能团的位置对于效力至关重要。吲哚环 4 位具有 5-氯吡啶酯的抑制剂 10 是最有效的抑制剂，其 SARS-CoV 3CLpro IC(50) 值为 30 nM，抗病毒 EC(50) 值为 6.9 microM。分子对接研究提供了这些抑制剂可能的结合模式。
• Protease inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US20020013360A1

  公开（公告）日：2002-01-31

  The invention relates to 3-hydroxy-and 3-keto-cyclohetero-substituted leucine compounds that are inhibitors of cysteine proteases, particularly cathepsin K, and are useful in the treatment of diseases in which inhibition of bone loss is a factor. The 3-hydroxy-or 3-keto-moiety is bonded to a tetrahydrothiophene, tetrahydrothiopyran, tetrahydrofuran or tetrahydropyran ring.

  本发明涉及3-羟基和3-酮基环杂基取代的亮氨酸化合物，它们是半胱氨酸蛋白酶抑制剂，特别是卡他普星K的抑制剂，并且在治疗骨质流失是一个因素的疾病中有用。 3-羟基或3-酮基基团与四氢噻吩，四氢噻吩，四氢呋喃或四氢吡喃环结合。
• Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination
  作者：Thanigaimalai Pillaiyar、Philipp Flury、Nadine Krüger、Haixia Su、Laura Schäkel、Elany Barbosa Da Silva、Olga Eppler、Thales Kronenberger、Tianqing Nie、Stephanie Luedtke、Cheila Rocha、Katharina Sylvester、Marvin R.I. Petry、James H. McKerrow、Antti Poso、Stefan Pöhlmann、Michael Gütschow、Anthony J. O’Donoghue、Yechun Xu、Christa E. Müller、Stefan A. Laufer

  DOI：10.1021/acs.jmedchem.2c00636

  日期：2022.7.14

  The main protease (Mpro, 3CLpro) of SARS-CoV-2 is an attractive target in coronaviruses because of its crucial involvement in viral replication and transcription. Here, we report on the design, synthesis, and structure–activity relationships of novel small-molecule thioesters as SARS-CoV-2 Mpro inhibitors. Compounds 3w and 3x exhibited excellent SARS-CoV-2 Mpro inhibition with kinac/Ki of 58,700 M–1

  SARS-CoV-2 的主要蛋白酶（M pro、 3CL pro）是冠状病毒中一个有吸引力的靶点，因为它在病毒复制和转录中发挥着至关重要的作用。在这里，我们报告了作为 SARS-CoV-2 M前抑制剂的新型小分子硫酯的设计、合成和构效关系。化合物3w和3x表现出优异的 SARS-CoV-2 M pro抑制作用，k inac / K i分别为 58,700 M –1 s –1 ( K i = 0.0141 μM) 和 27,200 M –1 s –1 ( K i = 0.0332 μM) ， 分别。在 Calu-3 和 Vero76 细胞中，化合物3h、3i 、 3l、3r、3v、3w和3x显示纳摩尔范围内的抗病毒活性，且没有宿主细胞毒性。完成了3w和3af与 SARS-CoV-2 M pro的共结晶，X 射线结构显示与蛋白酶的催化 Cys145 残基共价结合。有效的 SARS-CoV-2 Mpro
• Synthesis and SAR of p38α MAP kinase inhibitors based on heterobicyclic scaffolds
  作者：T.G. Murali Dhar、Stephen T. Wrobleski、Shuqun Lin、Joseph A. Furch、David S. Nirschl、Yi Fan、Gordon Todderud、Sidney Pitt、Arthur M. Doweyko、John S. Sack、Arvind Mathur、Murray McKinnon、Joel C. Barrish、John H. Dodd、Gary L. Schieven、Katerina Leftheris

  DOI：10.1016/j.bmcl.2007.07.029

  日期：2007.9

  The synthesis and structure-activity relationships (SAR) of p38 alpha MAP kinase inhibitors based on heterobicyclic scaffolds are described. This effort led to the identification of compound (21) as a potent inhibitor of p38a MAP kinase with good cellular potency toward the inhibition of TNF-alpha production. X-ray co-crystallography of an oxalamide analog (24) bound to unphosphorylated p38 alpha is also disclosed. (c) 2007 Elsevier Ltd. All rights reserved.